Issue link: https://www.e-digitaleditions.com/i/1532011
Calendar: The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. Inhalation February 2025 33 CALENDAR Please visit the industry organi- zations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations USP workshop: Hot topics in orally inhaled and nasal drug product performance testing e United States Pharmacopeia (USP) will host a workshop on March 19-20, 2025 at the US Pharmacopeial Convention in Rockville, Maryland, US. is in-person event about stan- dards for inhalation products will focus on the latest developments and best practices in orally inhaled and nasal drug products. e fol- lowing topics will be discussed by presenters from industry, aca- demia, US and European regula- tors, and the USP: • Orally inhaled products (OIPs): Aerodynamic particle size distribution (APDS) met- rics and data interpretation • OIPs: Abbreviated impactor measurement (AIM) as a com- plement to development and quality control • Compendial considerations for the presentation of OIP APSD data • Current considerations for nasal product performance tests To register: www.usp.org dose inhalers (MDI); nasal inhal- ers; and nebulizers, including the FOX™ device. Vectura also offers pharmaceutical analysis, process development, technical transfer, clinical trial supplies and regula- tory services. "e Vectura team is delighted with the completion of the acquisition," said Geraldine Venthoye, PhD, Chief Scientific Officer and Vice President for the Phillips Medisize Medical busi- ness. "We are excited about the opportunities and scale of Phil- lips Medisize, which will allow us to deliver our formulation and combination product expertise to more pharmaceutical customers as part of end-to-end pharmaceutical development," Paul Chaffin, Pres- ident of Phillips Medisize, added. "Phillips Medisize will continue to expand the services we offer phar- maceutical companies thanks to the acquisition of Vectura, partic- ularly in inhalation, to help meet growing patient needs." Hovione expands global spray drying capacity LISBON, PORTUGAL—Hov- ione announced completion of significant expansions in Europe and the US. e investments at its East Windsor, New Jersey, and Ringaskiddy, Cork, Ireland facili- ties will significantly increase Hov- ione's global spray drying capacity and enhance the sites' capabilities. In New Jersey, the investment is the first step of a multi-year site expansion program to advance spray drying and other capabil- ities. At the Cork facility, spray drying capacity increased nearly two-fold. New jobs were added at both locations. "Strengthen- ing our facilities and teams in the US and Ireland allows us to better serve our customers and provide flexible supply options for both small- and large-scale programs," said Jean-Luc Herbeaux, PhD, Chief Executive Officer, Hovione. Lonza and Iconovo to collaborate on development LUND, SWEDEN AND BASEL, SWITZERLAND—Iconovo AB and Lonza announced a collab- oration to develop spray-dried formulations of an intranasal biologic for Iconovo's propri- etary intranasal device, ICOone Nasal ® . is project, with a refor- mulated substance for obesity, is the first in Iconovo's initiative to reformulate known pharmaceu- ticals and replace injections and oral treatments with inhalation. e collaboration aims to iden- tify the ideal particle size, sta- bility and device compatibility while preserving biological activ- ity. Lonza will develop the spray- dried formulations at its Bend, Oregon, US site, which special- izes in addressing bioavailability challenges and modulating phar- macokinetics to meet target prod- uct profiles. "Our team at Lonza's respiratory center of excellence is pleased to work with Iconovo on its innovative applications, combining Lonza's particle engi- neering expertise with Iconovo's state-of-the-art devices, said Kim Shepard, Director of Advanced Drug Delivery. Delivering non- invasive and accessible therapies to patients in need is a focus area for both companies." Phillips Medisize completes acquisition of Vectura Group HUDSON, WISCONSIN, US— Molex, a parent to Phillips Medi- size, announced it has completed acquisition of Vectura Group from Philip Morris International, Inc. e transaction includes Vectura's proprietary technology and com- bination product development expertise in dry powder inhalers (DPIs), including the Lever Oper- ated Multi-dose Inhaler (LOMI) and Gyrohaler™ platforms; metered INDUSTRY NEWS continued from page 9